Scott R. Ward Joins Evident Vascular’s Board of Directors

Evident Vascular Inc. has welcomed Scott R. Ward to its Board of Directors.

With more than 40 years of experience in healthcare and medical technology, Ward most recently held key leadership roles, including CEO and chairman of Cardiovascular Systems Inc. before its acquisition by Abbott, and nearly 30 years at Medtronic plc, where he led the Cardiovascular, Neurological, and Diabetes businesses, driving transformative growth.

“We are thrilled to welcome Scott to the Evident Vascular Board,” Evident Vascular CEO Howard Rosen said. “Scott’s extensive experience and strategic vision will be instrumental as we continue to advance our AI-powered IVUS platform to improve clinical outcomes and expand adoption across peripheral and coronary vascular interventions.”

Beyond his executive career, Ward has served on more than 15 public and private company boards, chairs the Philanthropy Board at Gillette Children’s Hospital, and founded Raymond Holdings, a venture capital and advisory firm for medtech and life sciences.

Related: Medtech Startup Evident Vascular Makes Its Debut

Ward’s appointment reflects Evident Vascular’s commitment to assembling a team of visionary leaders to guide its strategic direction. His expertise aligns with the company’s focus on introducing a next-generation IVUS platform that addresses critical needs in the vascular imaging space.

“I am honored to join the Evident Vascular Board during this pivotal and exciting phase of the company’s journey,” Ward stated. “Evident’s innovative IVUS platform has the potential to redefine image guided therapy and significantly improve patient care. I look forward to contributing to the company’s growth and success.”

Evident Vascular Inc., is medical technology startup backed by Vensana Capital that is developing an advanced intravascular ultrasound (IVUS) platform technology designed initially for peripheral vascular interventions, with future capability for coronary procedures. Leveraging artificial intelligence (AI) to enable superior image interpretation and streamlined workflows, Evident Vascular’s technology has been designed to expand adoption of IVUS, driving increased market penetration and enabling improved clinical outcomes with faster, more accurate diagnosis and treatment decisions.